Greenwich Biosciences’ Spotlight highlights various aspects of our scientific research and cannabinoid clinical development program. We bring forward the voices of our dedicated employees and members of the medical, caregiver and advocacy community who make an invaluable contribution to our efforts.
Apr 25, 2018
In late 2017, when the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for an investigational cannabidiol (CBD) for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) and Dravet syndrome, it marked a significant milestone for Greenwich Biosciences.
Dec 21, 2017
At the AES Annual Meeting 2017 in Washington, DC, Greenwich Biosciences will continue its commitment to advance cannabinoid science by sponsoring several events and posters, including: